DOI:
10.1055/s-00033990
TH Open
LinksClose Window
References
Spyropoulos AC, Lipardi C, Xu J. et al.
Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study.
Clin Appl Thromb Hemost 2019;
25: 1076029619886022
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.